Table 5. Analysis of predictors of progression in 64 metastatic colorectal cancer patients.
| Progression | Non-progression | p-value | |
|---|---|---|---|
| Variables | (n = 35) (%) | (n = 29) (%) | |
| Age, years <65 years vs. ≧65 years) | 19 (54.3)/16 (45.7) | 17 (58.6)/12 (41.4) | 0.803 |
| Gender (female vs. male) | 14 (40.0)/21 (60.0) | 10 (34.5)/19 (65.5) | 0.796 |
| Chemotherapy/targeted therapy cycles (≥7 vs. =6) | 15 (42.9)/20 (57.1) | 21 (72.4)/8 (27.6) | 0.024* |
| Metastectomy location Liver Lung Ovary |
26 (74.3) 8 (22.9) 1 (2.9) |
20 (69.0) 7 (24.1) 2 (6.9) |
0.731 |
| Synchronous/Metachronous Synchronous Metachronous |
20 (57.1) 15 (42.9) |
16 (55.2) 13 (44.8) |
1.000 |
|
RAS Status Wild Mutant |
26 (74.3) 9 (25.7) |
27 (93.1) 2 (6.9) |
0.093 |
| Pre-treatment CEA (ng/ml) ≧5 <5 |
26 (74.3) 9 (25.7) |
19 (65.5) 10 (34.5) |
0.584 |
| Post-treatment CEA (ng/ml) ≧5 <5 |
17 (48.6) 18 (51.4) |
11 (37.9) 18 (62.1) |
0.454 |
| Targeted agents Cetuximab Bevacizumab |
21 (60.0) 14 (40.0) |
18 (62.1) 11 (37.9) |
1.000 |
| Grade III or more adverse effect Yes No |
6 (17.1) 29 (82.9) |
4 (13.8) 25 (86.2) |
1.000 |
Note: CEA = carcinoembryonic antigen.
*p-value < 0.05.